Skip to main content

Table 1 Baseline patient characteristics

From: Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Variable Values
Age (years) 51.1 ± 9.4
Sex
 Male 123 (65.4)
 Female 65 (34.6)
Duration of diabetes (years) 7.3 ± 4.9
Body weight (kg) 82.5 ± 14.6
BMI (kg/m2) 30.0 ± 4.4
Systolic blood pressure (mmHg) 132.3 ± 14.1
Diastolic blood pressure (mmHg) 80.6 ± 11.9
HbA1c (NGSP,  %) 7.8 ± 0.7
HbA1c (mmol/mol) 62.1 ± 7.5
Fasting plasma glucose (mg/dl) 156.2 ± 39.6
Current smokers 50 (26.7)
Drinking 89 (47.3)
eGFR (ml/min/1.73 m2)
 90 ≤ 65 (37.6)
 60 ≤, < 90 92 (53.2)
 45 ≤, < 60 15 (8.7)
 < 45 1 (0.6)
Complications
 Diabetic retinopathy 22 (11.8)
  Simple 13 (7.0)
  Pre-proliferative 3 (1.6)
  Proliferative 6 (3.2)
 Diabetic nephropathy 53 (28.2)
 Diabetic neuropathy 20 (10.6)
 Macrovascular complications 0 (0.0)
 Kidney disease 5 (2.7)
 Liver disease 51 (27.1)
 Hypertension 108 (57.4)
 Dyslipidemia 125 (66.5)
Oral hypoglycemic agents 185 (98.4)
 Sulphonylureas 68 (36.2)
 Biguanides 137 (72.9)
 α-Glucosidase inhibitors 27 (14.4)
 Glinides 7 (3.7)
 DPP-4 inhibitors 129 (68.6)
 Thiazolidinediones 31 (16.5)
Antihypertensive agents 102 (54.3)
Antidyslipidemic agents 96 (51.1)
Antithrombotic agents 6 (3.2)
  1. Data are shown as mean ± SD or as the number of patients (%)
  2. HbA1c glycosylated hemoglobin, DPP-4 dipeptidyl peptidase-4